.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Prof. Dr. Ulrike Protzer

Munich / DE

Technical University of Munich

Vorsitz

29.03.2023
08:30 – 10:00
Plenary Session
Immune response and pathology in COVID-19 (Joint Session with GfI)
Lecture hall 4/5

Weitere Beteiligungen

28.03.2023
Poster
P 292
Understanding the factors determining the fate of HBV-specific CD8 T cells elicited by therapeutic vaccination in low- and high-titer HBV infection
Adaptive immunity, Vaccines
28.03.2023
Poster
P 007
Generation and functional analysis of spacer modified HBV-specific chimeric antigen receptors that harbor a Fab fragment as binding domain
Adaptive immunity, Antiviral therapy and resistance
28.03.2023
Poster
P 235
Heterologous SARS-CoV-2 delta breakthrough infection elicits broader and more durable neutralizing antibody response than (non-breakthrough) infection
Epidemiology and public health, SARS-CoV-2
28.03.2023
Poster
P 240
SARS-CoV-2 productively infects human hepatocytes and induces cell death
SARS-CoV-2, Viral pathogenesis and persistence
28.03.2023
Poster
P 038
ATO (Arsenic Trioxide) impedes efficient HBV infection by interferance with PML-NBs
Antiviral therapy and resistance, Host cell factors and modulation
29.03.2023
13:30 – 13:45 12 Min. 3 Min.
Abstract Talk
O 067
A novel recombinant HBV based selection system allows for a systematic genomic knock-out screening and the identification of host factors involved in HBV infection
Viral vectors and gene therapy
29.03.2023
14:30 – 14:45 12 Min. 3 Min.
Abstract Talk
O 059
HBV core protein SUMOylation promotes PML association and productive HBV infection
Host cell factors and modulation, Viral replication strategies 2 (DNA viruses)
31.03.2023
10:45 – 11:00 12 Min. 3 Min.
Abstract Talk
O 115
MVA-HBVac – a novel vector for treatment of chronic hepatitis B via therapeutic vaccination
Adaptive immunity, Vaccines